Welcome to our dedicated page for DRNA news (Ticker: DRNA), a resource for investors and traders seeking the latest updates and insights on DRNA stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect DRNA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of DRNA's position in the market.
Dicerna Pharmaceuticals (Nasdaq: DRNA) announced the approval of inducement grants for a new employee, comprising stock options for 31,875 shares and 7,125 restricted stock units (RSUs). The stock options have an exercise price of $37.70, vesting over four years, with 25% on the first anniversary. RSUs will also vest over four years, starting at 25% after June 15, 2022. These grants comply with Nasdaq Rule 5635(c)(4). Dicerna focuses on RNA interference therapies targeting various diseases, and has multiple ongoing collaborations.
Dicerna Pharmaceuticals (Nasdaq: DRNA) has initiated patient dosing in its Phase 2 ESTRELLA trial for belcesiran, an investigational RNAi therapy targeting alpha-1 antitrypsin deficiency-associated liver disease (AATLD). This rare genetic condition affects approximately 183,000 individuals in Europe and the U.S., with liver transplantation as the primary treatment option. The ESTRELLA trial aims to evaluate the safety and efficacy of belcesiran, which aims to reduce the abnormal AAT protein, potentially restoring liver health.
Dicerna Pharmaceuticals (Nasdaq: DRNA) has completed dosing in the PHYOX™4 trial, evaluating the safety and tolerability of nedosiran for primary hyperoxaluria (PH) type 3 (PH3). This represents a crucial step as nedosiran aims to provide a treatment option for all PH types. Top-line results are expected in October 2021. The trial is part of a broader development program that supports the planned New Drug Application (NDA) submission in Q4 2021. Each year, approximately 8,500 people in the U.S. are affected by PH, with most remaining undiagnosed.
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) announced that CEO Douglas M. Fambrough will participate in a virtual fireside chat at the 42nd Annual Goldman Sachs Global Healthcare Conference on June 10, 2021, at 3:00 p.m. ET. The discussion will cover the company’s RNA interference (RNAi) therapeutics development. An audio webcast will be available on the Dicerna website, with an archived replay following the event. Dicerna focuses on therapies targeting disease-causing genes, leveraging its GalXC™ and GalXC-Plus™ technologies, with over 20 active programs in collaboration with major pharmaceutical partners.
Dicerna Pharmaceuticals (Nasdaq: DRNA) announced the FDA's acceptance of an IND application for LY3819469, a therapeutic candidate developed in partnership with Eli Lilly. This milestone triggers a $10 million payment to Dicerna and enables the initiation of a Phase 1 clinical trial targeting the LPA gene for cardiometabolic diseases. Under their collaboration, Dicerna may earn up to $350 million in milestones per hepatocyte target. The company continues to innovate with its GalXC™ RNAi technology platform, which is designed to silence disease-causing genes.
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) has announced the advancement of a GalXC™ RNAi candidate, DCR-LIV2, in collaboration with Boehringer Ingelheim for treating nonalcoholic steatohepatitis (NASH). This advancement has triggered a multimillion USD preclinical milestone payment expected in Q2 2021. Dicerna is eligible for up to $170 million in further milestones and tiered royalties on global sales. NASH is a chronic liver disease without approved treatments, affecting 1.5% to 6.5% of adults in the U.S.
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) recently announced participation in two major investor conferences. Douglas M. Fambrough, Ph.D., President and CEO, will host a fireside chat at the RBC Capital Markets Global Healthcare Conference on May 19 at 10:20 a.m. ET and provide a presentation at the Oppenheimer Rare & Orphan Disease Summit on May 21 at 8:00 a.m. ET. Audio webcasts will be available on the Company’s website, with archived replays afterward. Dicerna focuses on RNAi therapeutics aimed at treating various diseases.
Dicerna Pharmaceuticals (Nasdaq: DRNA) reported its Q1 2021 financial results, showing revenues of $47.6 million, up from $34.0 million in Q1 2020, driven by collaborations with Roche, Alexion, and Novo. The company experienced a net loss of $30 million or $0.39 per share, compared to a loss of $22.5 million or $0.31 per share a year earlier. Key upcoming milestones include pivotal trial data for nedosiran and the initiation of Phase 2 trials for belcesiran. Dicerna expects to sustain operations into 2024 with its cash reserves and collaboration revenues.
Dicerna Pharmaceuticals (Nasdaq: DRNA) announced it will release its Q1 2021 financial results on May 6, 2021, after market close. A conference call will follow at 4:30 p.m. ET, where management will discuss the results and provide a business update. Interested parties can access the call via phone or through Dicerna's website, where an archived version will also be available. The biopharmaceutical company focuses on RNA interference therapies targeting rare and common diseases, collaborating with top pharmaceutical firms on over 20 active programs.
Dicerna Pharmaceuticals (Nasdaq: DRNA) has agreed to sell its royalty interest in OXLUMO™ to Royalty Pharma (Nasdaq: RPRX) for an upfront payment of $180 million, plus potential sales-based milestones of up to $60 million. OXLUMO is FDA and EMA approved for treating primary hyperoxaluria type 1 and marketed by Alnylam Pharmaceuticals. This transaction is expected to extend Dicerna's cash runway into 2024, supporting ongoing clinical plans. The deal reflects Dicerna's commitment to addressing unmet medical needs in rare diseases, specifically primary hyperoxaluria.
